Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma
Glioblastoma is one of the most aggressive and treatment-resistant brain cancers known to medicine, carrying a median survival of just 12–15 months, even with the best available care.
Glioblastoma is one of the most aggressive and treatment-resistant brain cancers known to medicine, carrying a median survival of just 12–15 months, even with the best available care. This story matters for Science & Discovery readers tracking engineering. Reported by phys.org. Read the full original at the source link below.
Originally reported by phys.org. EngineeringNews.net curates and briefs the science & discovery stories that matter. Our editorial policy →
Get the daily engineering signal